| Title | Lentivector expressing HBsAg and immunoglobulin Fc fusion antigen induces potent immune responses and results in seroconversion in HBsAg transgenic mice |
| Authors | Hong, Yuan Peng, Yibing Mi, Michael Xiao, Haiyan Munn, David H. Wang, Gui-qiang He, Yukai |
| Affiliation | Peking Univ, Hosp 1, Dept Infect Dis, Beijing 100034, Peoples R China. Georgia Hlth Sci Univ, MCG Canc Ctr, Immunol Immunotherapy Program, Augusta, GA USA. Georgia Hlth Sci Univ, Dept Med, Augusta, GA USA. Georgia Hlth Sci Univ, Dept Pediat, Augusta, GA USA. Harvard Univ, Harvard Coll, Boston, MA 02115 USA. Peking Univ, Hosp 1, Dept Infect Dis, 8 Xisiku St, Beijing 100034, Peoples R China. |
| Keywords | Lentivector Hepatitis B virus Vaccines Genetic immunization Immunotherapy Chronic HBV infection T-CELL RESPONSES CHRONIC HEPATITIS-B DENDRITIC CELLS ANTITUMOR IMMUNITY IN-VIVO RECOMBINANT LENTIVECTOR THERAPEUTIC VACCINATION GENETIC IMMUNIZATION INFECTION LYMPHOCYTES |
| Issue Date | 2011 |
| Publisher | vaccine |
| Citation | VACCINE.2011,29,(22),3909-3916. |
| Abstract | Even though hepatitis B virus(HBV) vaccines effectively prevent new cases of HBV infection, with approximately 350 million patients worldwide, chronic HBV infection remains a major health problem because of the associated complications (such as liver cirrhosis and hepatocellular carcinoma) and the limited treatment options. Immunotherapy has the potential to effectively control HBV replication. In this current study, we found that recombinant lentivectors could induce potent HBV surface antigen (HBsAg) specific T cell responses and humoral immune responses. Tagging the HBsAg with immunoglobulin Fc fragment further substantially increased the HBsAg specific immune responses. Remarkably, the HBS-Fc-lv lentivector could effectively break immune tolerance and induce potent HBsAg specific adaptive immune responses in HBsAg transgenic (Tg) mice with low serum level of HBsAg. More importantly, the induction of HBsAg specific immune responses in Tg mice accompanied seroconversion from HBsAg to anti-HBsAg antibody (anti-HBsAb). Our study demonstrated the potential of utilizing lentivector to treat chronic HBV infection following reduction of viral load with antiviral drug therapy. (C) 2011 Elsevier Ltd. All rights reserved. |
| URI | http://hdl.handle.net/20.500.11897/160446 |
| ISSN | 0264-410X |
| DOI | 10.1016/j.vaccine.2011.03.025 |
| Indexed | SCI(E) |
| Appears in Collections: | 第一医院 |
